ENA Respiratory

Minimising the Impact of Viral Respiratory Infections

Melbourne, United Kingdom · Founded 2020 · $162.4M raised

Headquarters
Melbourne
Employees
1–10
Founded
2020
Business Model
B2B
Total Funding
$162.4M
Last Round
$114.0M Series AJun 2026
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defense enhancers for the prevention of severe complications from respiratory viral infections. Its lead product, INNA-051, is a first-in-class TLR2/6 agonist delivered as a self-administered nasal product with a weekly dosing regimen, currently in Phase II clinical trials. The company is headquartered in Melbourne, Australia, and was formed in 2020 as a spin-off from ENA Therapeutics Pty Ltd (now Axelia Oncology).

Summary

ENA Respiratory is a Biotech company based in Melbourne, United Kingdom, founded in 2020. It has raised $162.4M in total across 3 rounds, most recently a $114.0M Series A round in Jun 2026. Investors include Brandon Capital Partners, Bill & Melinda Gates Foundation and Uniseed.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJun 2026
$114.0M

Sign up to see all 3 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ENA Respiratory on Indexed.vc
<a href="https://indexed.vc/companies/ena-respiratory"><img src="https://indexed.vc/api/badge/company/ena-respiratory" alt="ENA Respiratory on Indexed.vc" width="260" height="76" /></a>